Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126893 | 1.00 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1ADORA3ADORA2A | |
| SCHEMBL2126896 | 1.00 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1ADORA3ADORA2A | |
| SCHEMBL7813772 | 0.90 | PTGS2 (0.42) | AKR1C3AKR1C2AKR1C1ADORA3ADORA2A | |
| SCHEMBL7813773 | 0.90 | PTGS2 (0.42) | AKR1C3AKR1C2AKR1C1ADORA3ADORA2A | |
| SCHEMBL1782770 | 0.89 | PTGS2 (0.46) | AKR1C3AKR1C2AKR1C1ADORA3ADORA2A | |
| SCHEMBL1079805 | 0.89 | PTGS2 (0.46) | AKR1C3AKR1C2AKR1C1ADORA3ADORA2A | |
| SCHEMBL7806930 | 0.89 | PTGS2 (0.46) | AKR1C3AKR1C2AKR1C1ADORA3ADORA2A | |
| SCHEMBL6024063 | 0.88 | TDP1 (0.43) | AKR1C3AKR1C2AKR1C1CA12CA1 | |
| SCHEMBL8663751 | 0.88 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7814069 | 0.88 | CA1 (0.52) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724362-B2 | Pharmaceutical compositions comprising nanoparticles and a resuspending material | BEND RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9545384-B2 | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate | BEND RESEARCH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2231169-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2162120-B1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2960253-A1 | HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 | Amgen Fremont Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9221915-B2 | Human monoclonal antibodies to activin receptor-like kinase-1 | PFIZER INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221915-B2 | Human monoclonal antibodies to activin receptor-like kinase-1 | PFIZER INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-8974827-B2 | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer | BEND RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8623883-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC | 2013-10-17 | — | — | US | disclosed |
| WO-2004093816-A2 | COMPOSITIONS COMPRISING A SELECTIVE COX-2 INHIBITOR AND A CALCIUM MODULATING AGENT | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093813-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CALCIUM MODULATING AGENT FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093811-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM ION CHANNEL BLOCKER FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093814-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM CHANNEL BLOCKER | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004060366-A1 | A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0891345-B1 | NOVEL FURAN DIARYLMETHYLIDENE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL USES THEREOF | UNION PHARMA SCIENT APPL (FR) | 2001-08-16 | — | — | EP | disclosed |
| US-6180651-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | BRISTOL-MYERS SQUIBB | 2001-01-30 | — | — | US | disclosed |
| WO-2000014082-A1 | DIARYLMETHYLIDENE FURAN DERIVATIVES AS DRUGS WITH ANTI-INFLAMMATORY, ANALGESIC AND CHEMOPREVENTIVE PROPERTIES | LABORATORIES UPSA (FR) | 2000-03-16 | — | — | WO | disclosed |
| EP-0891345-A1 | NOVEL FURAN DIARYLMETHYLIDENE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL USES THEREOF | LABORATOIRES UPSA (FR) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997037984-A1 | NOVEL FURAN DIARYLMETHYLIDENE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL USES THEREOF | LABORATOIRES UPSA (FR) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | AKR1C3 1216/4885AKR1C2 2191/4885AKR1C1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.